The disease is so uncommon that a review in 1983 included approximately 120 published cases.[1] So far, no definitive treatment has been defined.[1-3]
During a follow-up of 12 years, radiologic and clinical findings did not change. Spirometry performed at the last follow-up showed FEV1 as 2.71 (89% of predicted) and FEV1/FVC as 90.2% (103% of predicted). The roentgenologic appearance of the chest remained unchanged (Fig. 1b). Computed tomography of the chest showed bilateral calcific densities. She did not have pulmonary complaints and pulmonary function tests were in normal limits. A chest radiograph of her brother showed typical appearance of bilateral alveolar microlithiasis. He also did not have any pulmonary symptoms or signs.
Our patient had typical radiologic features and no pulmonary symptoms. During a 12-year follow-up, no clinical and radiologic progression was shown. Alveolar microlithiasis exhibits familial occurrence.[1] The roentgenogram of brother of our patient also showed bilateral sandlike nodulation with no pulmonary symptoms. Despite an apparent roentgenologic abnormality, there is little evidence indicating a need for therapeutic intervention. Pathologic studies have shown that, in most cases, the alveolar structures are remarkably well preserved. Some evidence suggests, however, that microliths form in the alveolar walls and subsequently extrude into the alveolar spaces.[1,2] Long-term follow-up of patients with alveolar microlithiasis show that aging process per se is associated with a restrictive type of deterioration rather than diminution in lung function,[1] allowing most of the patients to remain symptom-free.
Caffrey and Altman[2] identified alveolar microlithiasis in premature twins, and suggested that it might have originated in utero resulting from an enzyme defect. It was also postulated that the disease was due to an inborn error of the respiratory metabolism at the alveolar interface, but thus far this theory has not been substantiated.[3]
No known therapy exists for pulmonary alveolar microlithiasis. The disease is reported to be unresponsive to corticosteroids and chelating agents. Treatment has been purely supportive and alleviative in a subset of patients. Bronchopulmonary lavage has been tried, but has had no effect on the course of the disease.[4] Moreover, the need for treatment has not been justified since the disease remains unchanged in a majority of patients. Similarly, our patient, together with her brother, remained symptom-free for 12 years without the need for any treatment.
In conclusion, alveolar microlithiasis is a pulmonary disease with no known therapy and cause. In some patients, the disease does not show progression in longterm follow-up. It may be speculated that no treatment is necessary in patients showing no development. Further studies with larger series are needed to justify the need for treatment.
1) Prakash UB, Barham SS, Rosenow EC 3rd, Brown ML, Payne WS. Pulmonary alveolar microlithiasis. A review including ultrastructural and pulmonary function studies. Mayo Clin Proc 1983;58:290-300.
2) Caffrey PR, Altman RS. Pulmonary alveolar microlitbiasis occurring in premature twins. J Pediatr 1965;66:758-63.